GPCR logo

Structure Therapeutics Inc

GPCR

Build a strategy around GPCR

Accountable AI Logo

Structure Therapeutics Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-17

Snapshot

  • Zero revenue pre-clinical biotech burning 196M FCF TTM with 103M cash - runway under 6 months without financing[Free Cash Flow TTM]
  • R&D spend of 190M TTM (77% of opex) signals aggressive pipeline investment; 4.2x industry median R&D[Research and Development TTM]
  • Trading at 4.6x book with zero revenue - 3.5B market cap pricing in significant clinical success[P/B Ratio]

Watch Triggers

  • Cash and Equivalents: Falls below 75M or no financing announced within 90 daysTriggers forced financing at unfavorable terms or strategic sale
  • Research and Development TTM: Drops >20% QoQ without pipeline progressSignals cash preservation mode or abandoned programs
  • Net Common Stock Issuance: Exceeds 100M in single quarterMajor dilution event reprices equity significantly

Bull Case

Clean balance sheet (debt/equity 0.9%) with 770M equity provides financing flexibility; recent 57M raise shows capital access

Debt to EquityCommon Stockholders Equity

Heavy R&D investment (190M) in GPCR-targeted therapeutics positions for potential blockbuster in obesity/metabolic space

Research and Development TTMMarket Cap TTM

Bear Case

Sub-6-month cash runway at current burn creates existential financing risk; dilution or unfavorable terms likely

Cash and EquivalentsFree Cash Flow TTM

3.5B valuation on zero revenue requires multiple clinical wins; binary outcomes typical for pre-revenue biotech

Total Revenue TTMEnterprise Value

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
30%

Leverage GPCR's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Cash runway crisis likely forces dilutive financing or partnership within 6 months

3-12mhigh
  • 103M cash vs 196M annual burn rate
  • 57M net stock issuance TTM shows financing pattern
  • Working capital 756M mostly invested, not liquid
Cash position 103M, FCF -196M TTMNet stock issuance 57M TTMInvestment purchases 249M TTM

Valuation Context

Caveats

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.